New drug combo targets hard-to-treat cancers with KRAS mutation

NCT ID NCT06128551

Recruiting now Disease control Sponsor: Revolution Medicines, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung, colorectal, or pancreatic cancer that has not responded to standard treatments will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

appendiceal neoplasm bronchial neoplasm colonic neoplasm colorectal cancer colorectal neoplasm digestive system neoplasm endometrium neoplasm Esophageal Neoplasms gastric neoplasm intestinal cancer lung disorder lung neoplasm neoplasm Neoplasm Metastasis Neoplasms by Site non-small cell lung carcinoma ovarian cancer pancreatic ductal adenocarcinoma pancreatic neoplasm rectal neoplasm respiratory system disorder respiratory tract neoplasm Thoracic Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER NON-SMALL CELL LUNG CANCER (NSCLC) PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

AUSL Romagna - S.M. delle Croci Hospital
RECRUITING

Ravenna, 48121, Italy
Allegheny Health Network
RECRUITING

Pittsburgh, Pennsylvania, 15212, United States
CHU Nantes
RECRUITING

Nantes, 44093, France
Cancer Institute of Montpellier
RECRUITING

Montpellier, 34298, France
Centre Leon Berard
RECRUITING

Lyon, 69373, France
Centro Di Riferimento Oncologico
RECRUITING

Aviano, 33081, Italy
City of Hope
WITHDRAWN

Duarte, California, 91010, United States
Columbia University
RECRUITING

New York, New York, 10032, United States
Community Health Network
RECRUITING

Indianapolis, Indiana, 46250, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Department of Medical Oncology - Azienda Ospedaliero Uniersitaria delle Marche
RECRUITING

Ancona, 60126, Italy
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Fundacion MD Anderson Cancer Center
RECRUITING

Madrid, 28033, Spain
Henry Ford Cancer
WITHDRAWN

Detroit, Michigan, 48202, United States
Hospital Louise Pradel
RECRUITING

Bron, 69500, France
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Hospital Universitario Miguel Servet
RECRUITING

Zaragoza, 50009, Spain
Hospital Universitario Virgen Macarena
RECRUITING

Seville, 41009, Spain
Institut Bergonie
RECRUITING

Bordeaux, 33000, France
Institut Catala d'Oncologia Hospital
RECRUITING

Barcelona, 08908, Spain
Institute Romagnolo per lo Studio Tumori
RECRUITING

Meldola, 47014, Italy
Institute of Cancer of Strasbourg
WITHDRAWN

Strasbourg, 67033, France
Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"
RECRUITING

Naples, 80131, Italy
Klinikum Esslingen GmbH
RECRUITING

Esslingen am Neckar, 73730, Germany
Klinkum Nurnberg Paracelsus Medical Unviersity
RECRUITING

Nuremberg, 90419, Germany
Krankenhaus Bethanien Moers
RECRUITING

Moers, 47441, Germany
La Fe University and Polytechnic Hospital
RECRUITING

Valencia, 46026, Spain
MD Anderson
RECRUITING

Houston, Texas, 77030, United States
Mary Crowley Cancer Research
COMPLETED

Dallas, Texas, 75230, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Moffitt Cancer Center and Research Institute
RECRUITING

Tampa, Florida, 33612, United States
NEXT Dallas
RECRUITING

Irving, Texas, 75039, United States
NEXT Oncology - Quirónsalud Madrid University Hospital
RECRUITING

Madrid, 28223, Spain
NEXT Oncology San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
NEXT Oncology Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
NYU Langone Health
RECRUITING

New York, New York, 10032, United States
Netherlands Cancer Institute Antoni van Leeuwenhoek
RECRUITING

Amsterdam, 1066CX, Netherlands
Niguarda Cancer Center
RECRUITING

Milan, 20162, Italy
Oscar Lambret Center of Lillle
RECRUITING

Lille, 59000, France
Pan American Center for Oncology Trials
RECRUITING

San Juan, 00935, Puerto Rico
START Barcelona - Hospital HM Nou Delfos
RECRUITING

Barcelona, 08023, Spain
START Madrid
RECRUITING

Madrid, 28040, Spain
START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
START Texas
RECRUITING

San Antonio, Texas, 78229, United States
San Luigi Hospital
RECRUITING

Orbassano, 10043, Italy
Sarah Cannon Research Institue
RECRUITING

Nashville, Tennessee, 37203, United States
Stanford Cancer Institute
RECRUITING

Stanford, California, 94305, United States
UC Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States
UC IRVINE Health
RECRUITING

Orange, California, 92868, United States
University Clinic of Navarra
RECRUITING

Madrid, 28027, Spain
University Clinic of Navarra
RECRUITING

Pamplona, 31008, Spain
University of Colorado Cancer Center
RECRUITING

Aurora, Colorado, 80045, United States
University of Oklahoma
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
Universitäts Klinikum Köln
RECRUITING

Cologne, 80937, Germany
West Cancer Institute
RECRUITING

Angers, 49055, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.